The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his ...
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources ...
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over ...
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial ...
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study ...
Themis Bioscience’s Chikungunya Vaccine Study Results Published
Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability.
Moderna and Institut Pasteur Sign Strategic Research Collaboration
Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ and the Institut Pasteur, today announced a long-term strategic research collaboration for the discovery and development of drugs and vaccines using Moderna’s mRNA Therapeutics™ platform. Valera, a Moderna venture company, will manage the research collaboration for Moderna.
Patronage: the Institut Pasteur and the Total Foundation renew their common commitment against infectious diseases
For 10 years, Total and its corporate foundation working alongside the Institut Pasteur and its International Network in the fight against infectious diseases. A new sponsorship agreement, of EUR 6 million for three years, was signed on 26 January 2015. It will provide funding, for public health and research projects in resource limited countries in order to better understand the therapeutic and vaccine responses in children.
Ebola: Study of the chains of transmission in Conakry
Researchers at the Institut Pasteur of Dakar and the Institut Pasteur in Paris have reconstructed chains of transmission of Ebola virus in the capital city of Guinea, from February to August 2014. The data show the positive impact of control measures on the evolution of the epidemic but highlight the challenges of Ebola control in large urban centres.
In a biological sense, what does it mean to be “in good health”? This far-reaching question is the focus of the “Laboratoire d'Excellence” project Milieu Intérieur (“Environment Within”). The Milieu Intérieur cohort is the first French cohort of its kind, comprised of a thousand healthy donors. Studying this cohort will help define the parameters of a healthy immune system. The recent analysis of the initial results generated from the cohort represents an important milestone for the scientists in this consortium.
Identification of an Achilles heel in the dengue virus gives new hope for vaccine development
Scientists have identified a vulnerable site on the surface of the dengue virus which is targeted by the only broadly neutralizing antibodies identified to date. This discovery offers a new target for the development of a vaccine to combat all four types of dengue virus currently in circulation.
Malaria: formal identification of the artemisinin resistance gene
Together with teams from Columbia University (USA), CNRS in Toulouse and NIH/NIAID (USA), Institut Pasteur scientists based in Paris and Cambodia have recently provided the key demonstration that K13 is indeed the main determinant of artemisinin resistance in Plasmodium falciparum parasites. This work is a landmark for the scientific community, as it provides a validated molecular marker for artemisinin resistance, which currently poses a major public health problem. This work is published in the journal Science.
The Institut Pasteur will host on the 12th of December 2014 the 2nd ceremony in honor of its graduating PhD class, with the Doctors having defended in 2013-2014. This ceremony will be chaired by Pr Christian Bréchot, President of the Institut Pasteur. It will be held in presence of Jean-Philippe Pierre, deputy mayor of the 15th arrondissement of Paris.
Ebola: a new Institut Pasteur is soon to be created in Guinea
Pr Christian Bréchot, President of the Institut Pasteur, will be in Guinea Friday 28th November 2014, alongside François Hollande, President of the French Republic. Two agreements will be signed, one with the government of Guinea and the other one with the French Agency for Development (AFD), allowing for the creation of a new Pasteur Institute in Conakry in late 2016. On Saturday 29th, Pr. Bréchot will visit the Macenta treatment Center where the Institut Pasteur is setting-up a diagnostic laboratory.
Chikungunya fever: Themis Bioscience’s vaccine candidate successful in phase 1
The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate was developed under a R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) based upon a measles vaccine vector technology.